Vasohibin: the Feedback on a New Inhibitor of Angiogenesis

Overview

Journal J Clin Invest

Specialty General Medicine

Date 2004 Oct 7

PMID 15467823

Citations 17

Authors

Robert S Kerbel

Affiliations

Soon will be listed here.

Abstract

Angiogenesis is regulated in large part by the balance of various proangiogenic stimulators, such as VEGF, and a diverse group of endogenous inhibitors of angiogenesis, most of which are extrinsic to endothelial cells. With respect to the latter, until recently, none have appeared to be induced as a consequence of a specific, self-regulating, feedback inhibition response. A new inhibitor, called vasohibin, has been uncovered. Vasohibin is selectively induced in endothelial cells by proangiogenic stimulatory growth factors such as VEGF; it appears to operate as an intrinsic and highly specific feedback inhibitor of activated endothelial cells engaged in the process of angiogenesis.

Citing Articles

EB1-dependent long survival of glioblastoma-grafted mice with the oral tubulin-binder BAL101553 is associated with inhibition of tumor angiogenesis.

Berges R, Tchoghandjian A, Serge A, Honore S, Figarella-Branger D, Bachmann F Oncotarget. 2020; 11(8):759-774.

PMID: 32165998 PMC: 7055546. DOI: 10.18632/oncotarget.27374.

N6-methyladenosine induced miR-143-3p promotes the brain metastasis of lung cancer via regulation of VASH1.

Wang H, Deng Q, Lv Z, Ling Y, Hou X, Chen Z Mol Cancer. 2019; 18(1):181.

PMID: 31823788 PMC: 6902331. DOI: 10.1186/s12943-019-1108-x.

Association between TAp73, p53 and VASH1 expression in lung adenocarcinoma.

Wu M, Zhang Z, Ma F, Zhang X, Zhang Z, Tang J Oncol Lett. 2018; 15(4):5175-5180.

PMID: 29552154 PMC: 5840712. DOI: 10.3892/ol.2018.7912.

The expression of vasohibin-1 and its prognostic significance in bladder cancer.

Zhang B, Wu Z, Xie W, Tian D, Chen F, Qin C Exp Ther Med. 2017; 14(4):3477-3484.

PMID: 29042936 PMC: 5639433. DOI: 10.3892/etm.2017.4969.

The roles of vasohibin and its family members: Beyond angiogenesis modulators.

Du H, Zhao J, Hai L, Wu J, Yi H, Shi Y Cancer Biol Ther. 2017; 18(11):827-832.

PMID: 28886304 PMC: 5710674. DOI: 10.1080/15384047.2017.1373217.

References

Hanahan D, Bergers G, Bergsland E . Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest. 2000; 105(8):1045-7. PMC: 300842. DOI: 10.1172/JCI9872. View

Hanahan D, Folkman J . Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996; 86(3):353-64. DOI: 10.1016/s0092-8674(00)80108-7. View

Dameron K, Volpert O, Tainsky M, BOUCK N . Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science. 1994; 265(5178):1582-4. DOI: 10.1126/science.7521539. View

Kalas W, Gilpin S, Yu J, May L, Krchnakova H, Bornstein P . Restoration of thrombospondin 1 expression in tumor cells harbouring mutant ras oncogene by treatment with low doses of doxycycline. Biochem Biophys Res Commun. 2003; 310(1):109-14. DOI: 10.1016/j.bbrc.2003.08.128. View

Filleur S, Courtin A, Ait-Si-Ali S, Guglielmi J, Merle C, Harel-Bellan A . SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth. Cancer Res. 2003; 63(14):3919-22. View

Folkman J . Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971; 285(21):1182-6. DOI: 10.1056/NEJM197111182852108. View

Volpert O, Zaichuk T, Zhou W, Reiher F, Ferguson T, Stuart P . Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat Med. 2002; 8(4):349-57. DOI: 10.1038/nm0402-349. View

Kalluri R . Discovery of type IV collagen non-collagenous domains as novel integrin ligands and endogenous inhibitors of angiogenesis. Cold Spring Harb Symp Quant Biol. 2003; 67:255-66. DOI: 10.1101/sqb.2002.67.255. View

Filleur S, Volpert O, Degeorges A, Voland C, Reiher F, Clezardin P . In vivo mechanisms by which tumors producing thrombospondin 1 bypass its inhibitory effects. Genes Dev. 2001; 15(11):1373-82. PMC: 312711. DOI: 10.1101/gad.193501. View

10.

. Pieces of eight: bioactive fragments of extracellular proteins as regulators of angiogenesis. Trends Cell Biol. 1997; 7(5):182-6. DOI: 10.1016/S0962-8924(97)01037-4. View

11.

Hamano Y, Sugimoto H, Soubasakos M, Kieran M, Olsen B, Lawler J . Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res. 2004; 64(5):1570-4. DOI: 10.1158/0008-5472.can-03-3126. View

12.

Ferrara N, Hillan K, Gerber H, Novotny W . Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004; 3(5):391-400. DOI: 10.1038/nrd1381. View

13.

BOUCK N, Stellmach V, Hsu S . How tumors become angiogenic. Adv Cancer Res. 1996; 69:135-74. DOI: 10.1016/s0065-230x(08)60862-3. View

14.

Yu J, Rak J, Coomber B, Hicklin D, Kerbel R . Effect of p53 status on tumor response to antiangiogenic therapy. Science. 2002; 295(5559):1526-8. DOI: 10.1126/science.1068327. View

15.

Folkman J . Tumor angiogenesis. Adv Cancer Res. 1985; 43:175-203. DOI: 10.1016/s0065-230x(08)60946-x. View

16.

Rafii S, Lyden D, Benezra R, Hattori K, Heissig B . Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?. Nat Rev Cancer. 2002; 2(11):826-35. DOI: 10.1038/nrc925. View

17.

Watanabe K, Hasegawa Y, Yamashita H, Shimizu K, Ding Y, Abe M . Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis. J Clin Invest. 2004; 114(7):898-907. PMC: 518662. DOI: 10.1172/JCI21152. View

18.

Lindner D . Interferons as antiangiogenic agents. Curr Oncol Rep. 2002; 4(6):510-4. DOI: 10.1007/s11912-002-0065-4. View

19.

Langer R, Brem H, Falterman K, Klein M, Folkman J . Isolations of a cartilage factor that inhibits tumor neovascularization. Science. 1976; 193(4247):70-2. DOI: 10.1126/science.935859. View

20.

Kerbel R, Folkman J . Clinical translation of angiogenesis inhibitors. Nat Rev Cancer. 2002; 2(10):727-39. DOI: 10.1038/nrc905. View